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This paper aims to present the importance of the benchmark dose (BMD) as a point of 
departure (the lowest dose or concentration in the experiment that deviates from the response that 
differs from the normal response) in toxicological risk assessment, as well as to present commonly 
used software for its calculation (BMDS and PROAST). Benchmark dose is defined as a statistical 
lower confidence limit of a dose that results in a small change in effect (5-10%) in comparison 
with the control value. The BMD approach is considered a substitution for the NOAEL approach, 
which uses the highest observed no-effect level (NOAEL) to obtain the reference dose. The BMD 
approach is a methodically more forward-thinking technique than the NOAEL approach because 
it has statistical power and provides a wide range of dose-response relationships and allows the 
determination of their uncertainty and variability. Moreover, the BMD approach contributes to 
the reduction of experimental animals in toxicity studies. Therefore, the European Food Safety 
Authority (EFSA) recommends the use of BMDL10 values for quantal and BMDL05 for continuous 
data. 
 





Human health risk assessment 
Human health risk assessment is the process of data analysing to determine whether 
a chemical might lead to adverse effects in the exposed subjects (1,2). It includes the 
characterization and quantification of potential harmful effects on human health 
associated with exposure to chemicals (1–3). Four steps of risk assessment are: hazard 
identification (assessment of whether the agent produces a toxic effect), hazard 
characterization (dose-response modelling), exposure assessment, and risk 
characterization (4). One of the main objectives of risk assessment is to establish 
acceptable levels of human exposure, the so-called ’safe’ values, necessary for safety 
evaluation of impurities in active pharmaceutical ingredient (API) or drug product, as 
well as setting up regulations regarding industrial and environmental chemicals, food 
additives, pesticide residues, etc. (3). The next crucial step in the process of obtaining 
safe values is the determination of Point of Departure (POD) - the lowest dose or 
concentration that causes a response in the experiment that deviates from the normal 
response and poses toxicological relevance. To eliminate the differences between the 
experimental data, POD must be extrapolated or modified by the safety factors. In this 
step, the following uncertainties should be considered: differences between species, 
differences within species, differences in length of exposure, database quality, etc. (5,6).  
Two main approaches can be used for estimating POD, No Observable Effect Level 
(NOAEL), and Benchmark Dose (BMD) approach (3, 6).  
This paper aims to present the use of BMD as a Point of Departure in estimating 
the dose-response relation, compare BMD with the NOAEL approach underlining their 
most important advantages and disadvantages, as well as to describe the most commonly 
used software for BMD calculation (BMDS and PROAST).  
BMD history 
Crump was the first to propose BMD approach in 1984. Originally, this 
methodology was intended only for quantal data (7). Nevertheless, in 1995, its use was 
extended to include continuous data as well (8). Somewhat later, a regression approach 
was introduced, with the aim to obtain POD even at low dose levels (9,10). In 2005, the 
European Food Safety Agency (EFSA) recommended the application of BMD for 
evaluation of non-threshold effects (i.e. for genotoxic and carcinogenic substances) (11). 
In 2009, the recommendation was broadened to include the evaluation of risks of all 
substances, using experimental and epidemiological data (12). Today, even the World 
Health Organization (WHO) recommends the use of BMD in human health risk 
assessment (13).  
By definition, BMD is considered a dose that results in a small change in effect (5-
10%) in comparison with the control value. The variability and uncertainty of the data are 




limits. The statistical lower confidence limit was formerly called the benchmark dose (7), 
but soon became recognised as a BMD lower limit (BMDL) (12). This methodology is 
considered a substitute for the NOAEL approach, which uses NOAEL, or lowest observed 
adverse effect level (LOAEL) (4). 
NOAEL approach for POD calculation 
NOAEL approach can be applied to all toxicological effects under the condition 
that they have a threshold. It has long been used in regulatory processes for assessing the 
health risks of substances in food, especially to determine tolerable daily intake (TDI) or 
tolerable weekly intake (TWI) for contaminants, permitted daily exposure (PDE) for 
elemental impurities and residual solvents in medicinal products, as well as acceptable 
daily intake (ADI) for food additives and pesticide residues (12). 
In the NOAEL approach, for each monitored effect, the highest non-toxic dose is 
determined. The lowest relevant NOAEL of all the toxic effects identified in the study is 
marked as the critical NOAEL of the study. 
In other words, NOAEL represents the highest tested dose that does not lead to a 
toxic effect in a particular experiment. NOAEL's numerical value highly depends on the 
choice of dose levels in the study design process, as well as on the study ability to detect 
adverse effects. Given that the number of animals used in studies is limited, and that the 
test methods are not sensitive enough to detect low effects, the experiments, particularly 
older ones, usually resulted in very high NOAEL values. In the case that significant effect 
is observed at all selected dose levels, LOAEL may be used in further risk assessment, 
including additional safety factors (12). 
Thus, in the NOAEL approach, the shape of the dose-response curve is not taken 
into account. Moreover, this approach heavily depends on the choice of dose intervals 
and the number of experimental animals, together with the sensitivity of the methods to 
identify the critical effect (12). Particularly, this concept is not sufficiently reliable for the 
risk evaluation in the case of genotoxic carcinogens, where it is assumed that even one 
molecule might induce toxic response relevant to humans. It is generally accepted that 
chemical risk assessment in animal studies at human exposure levels can be improved by 
creating a dose-response curve to better characterize and quantify potential risks (14).  
BMD approach for POD calculation 
The BMD approach is of particular importance for 1) situations where NOAEL 
cannot be identified; 2) determination of the Margin of Exposure (MOE) in the case of 
non-threshold effects (genotoxic and carcinogenic substances); as well as 3) assessment 
of the dose-response ratio of epidemiological studies data (12). 
The BMD approach has mostly been applied in the developmental toxicity studies 




the other ways in which the BMD approach could be applied in toxicology (18,20–29). 
The experience of our research group includes the use of a BMD approach in evaluating 
the toxic effects of decabrominated diphenyl ether BDE-209 in subacute orally exposed 
Wistar rats (Figure 1A) (25, 28), as well as polychlorinated biphenyls after subacute oral 
exposure of rats (23,27). Also, for the first time, Antonijevic et al. have introduced BMD 
to assess the effectiveness of antidote in a study in which acute i.m. dichlorvos exposure 
of rats was followed by the reactivation of acetylcholinesterase in erythrocytes and 
diaphragm by K203 and K027 oximes (Figure 1B) (24,26,29). It can also be applied to 
establish health based exposure limits in risk identification in the process of manufacture 
of various medicinal products in shared facilities (30). Furthermore, the BMD approach 
can be used to assess risks in ecotoxicology (18,31). For example, in ecotoxicological 
toxicity tests (i.e. reproductive toxicity tests on daphnia and oyster larvae), conducted to 
investigate the impact of certain pollutants or their mixtures on the environment (18). 
Benchmark modelling is relatively simple. Experimental data are fitted into the 
flexible mathematical models. The next step is the determination of a dose linked to a 
defined response level. The defined response level is marked as Benchmark Response 
(BMR), with BMD being its corresponding dose (12). The advantage was given to a 95% 
lower BMD confidence limit (BMDL), until, in 2017, EFSA recommended describing 
the entire confidence interval, including the BMD upper limit, BMDU, implying that two-
sided approach should be set in software for calculations (32,33). 
The BMD approach can be used in the assessment of nearly all toxicological effects. 
It includes taking into account all dose-response data during the estimation of the total 
dose-response curve shape for a given endpoint. 
The first step in the BMD approach includes determination of low but measurable 
response level (e.g. 5%, 10%, or higher increase or decrease in response in comparison 
with the response in the control group, depending on the effect), i.e. BMR. The next step 
involves fitting a group of dose-response models and calculating BMD, BMDL, and 
BMDU for those that illustrate the data following statistical criteria. This means that the 
minimum dataset for BMD calculation should show a biologically/statistically significant 
dose-related trend for the particular endpoint. This step results in a range of BMDL values 
for each examined toxic effect. BMDL is selected for each investigated effect and the 
critical BMDL value of the study is determined from the range of BMDL values for the 
various observed effects. 
The BMD approach can be applied to any toxic effect observed in appropriate 
studies, while the toxic effect with the lowest BMDL is considered the critical effect of 
the study. Based on the review of numerous experimental studies, Allen et al. (1994) 
deduced that, amongst the tested BMD levels, BMDL05 can be characterized as the most 
similar to the NOAEL values determined by statistical tests (16). Participants in a BMD 




substituted with the BMD concluded that BMDL05 or BMDL10 should be applied to all 
quantal non-carcinogenic toxic effects (34). Furthermore, EFSA proposes that BMR of 
10% (BMDL10) should be used for quantal and BMR of 5% (BMDL05) for continuous 











Figure 1. The example of the Benchmark approach (PROAST software); In the PROAST  
 report for continuous data, the terms critical effect size (CES) and critical effect  
 dose (CED) are used instead of the term Benchmark response (BMR) and  
 Benchmark dose (BMD). (A) Effect of cadmium and cadmium in combination  
 with decabromodiphenyl ether (BDE209) in doses 1000, 2000, 4000 mg/kg bw/day  
 on the concentration of -SH groups in brain homogenates of Wistar rats; (B) Ratio  
 of oxime K027 (triangles, black curve) and oxime K203 (crosses, red curve) doses  
 and ACHE activity in the erythrocyte mucus of Wistar rats poisoned with  
 dichlorvos. The curves represent a fitted exponential model, which includes the  
 calculation of the relative potency factor (RPF) as a parameter of the model. RPF  
 expresses the Critical Effect Dose (CED) of oxime K027 versus CED of oxime  
 K203 (RPF> 1, higher potency, lower CED). The values of RPF-K027 (unnamed  
 number), CED-K203 (µmol / kg) together with 90% confidence interval are shown  
 in the legend to the right of each graph. The vertical and horizontal dashed lines  
 represent RPF-K027 and CEDK203 for the critical effect size (CES) of 58%. 
Slika 1.  Primer benchmark pristupa (PROAST softver); U izveštaju PROAST softvera za  
 kontinuirane podatke koriste se pojmovi veličina kritičnog efekta (engl. critical  
 effect size, CES) i kritična doza (engl. critical effect dose, CED) umesto termina  
 benchmark odgovor (engl. Benchmark response BMR) i benchmark doza (engl.  
 Benchmark dose, BMD), redom. (A) Dejstvo kadmijuma i kadmijuma u  
 kombinaciji sa dekabromovanim difeniletrom (BDE209) u dozama 1000, 2000,  




 pacova; (B) Odnos doze oksima K027 (trouglovi, crna kriva) i oksima K203  
 (krstići, crvena kriva) i ACHE aktivnosti u eritrocitima Wistar pacova trovanih  
 dihlorvosom. Krive predstavljaju fitovani eksponencijalni model, koji uključuje  
 izračunavanje relativnog faktora potentnosti (engl. relative potency factor, RPF)  
 kao parametra modela. RPF izražava CED oksima K027 nasuprot CED oksima  
 K203 (RPF > 1, veća potentnost, niži CED). Vrednosti RPF-K027 (neimenovani  
 broj), CED-K203 (µmol/kg) zajedno sa intervalom pouzdanosti od 90% prikazani  
 su u legendi desno od svakog grafika. Vertikalne i horizontalne isprekidane linije  
 predstavljaju RPF-K027 i CED-K203 za CES od 58%.  
 
In the BMD approach, statistical methods are used to extract the information from 
a whole data set, rather than comparing subgroups of the data. Additionally, the BMD 
approach can interpolate among administered doses, which is not the case with the 
NOAEL approach. This means that BMDL is linked to a predefined effect size for which 
the suitable dose is estimated. Contrarily, NOAEL represents a predefined dose, while 
the corresponding potential effect size is not calculated. Therefore, BMDL provides more 
information than NOAEL. The BMD approach is characterized by an uncertainty estimate 
in the calculated BMD: it is expressed by the BMD confidence interval, which is not 
usually done in the NOAEL approach. This distinction between the two approaches is 
particularly important in cases where there is a  limited number of data or values are very 
scattered. Although NOAEL approach can often be applied in such cases, uncertainty in 
the resulting values is not calculated in most of the cases (12,32,33). 
The impact of the sample size on NOAEL and BMDL 
One of the major differences between the NOAEL and BMD approach is how they 
are affected by the sample size (7,18). In the NOAEL approach, the responses of treated 
groups are compared with the response of the control group. The likelihood of obtaining 
a statistically significant difference lowers with the decrement in experimental animals’ 
number and thus results in a higher NOAEL value and consequently, higher 
recommended reference values concerning human health and safety. Contrariwise, in the 
BMD approach, BMDL increases with the increase of experimental animals’ number per 
dose group. Having in mind that BMDL represents the lower BMD confidence interval, 
a larger study will have a smaller BMD confidence interval as an outcome and, therefore, 
a higher BMDL value (18). 
BMD approach and 3R rule 
The BMD approach could be counted a significant step forward regarding the 3R 
rule - replacing experimental animals wherever possible by alternative methods or species 
that are lower on the phylogenetic scale, reducing the number of animals, and refinement 




BMD approach supports 3R rule, especially the reduction of experimental animals’ 
number, having in mind that it is a scientifically better and more precise method of dose-
response data analysis compared to the NOAEL approach. The reduction of experimental 
animal numbers can be contributed in two ways. Firstly, the information (e.g. POD) that 
can be obtained from a data set is more accurate when applying the BMD approach 
compared to the NOAEL. Secondly, the same quality information (e.g. the accuracy of 
the obtained POD) can be achieved by using fewer animals (35,36). 
Software packages for BMDL determination  
The two most commonly used BMDL software packages are BMDS (Benchmark 
Dose Software, BMDS), created by the US Environmental Protection Agency (US EPA), 
and PROAST, created by the National Institute of Public Health and the Netherlands 
National Institute for Public Health and the Environment (RIVM) (33, 34).  
The main differences between the two software packages include the following:  
 The predefined settings in PROAST software include the log-normal data 
distribution, while, in the BMDS software, normal distribution of continuous 
data is set as a default (34). 
 Currently, BMDS software does not allow covariance to be included in the 
analysis, while this possibility exists in PROAST (34). 
 BMDS is not suitable for studies with a large number of individual data (e.g. 
epidemiological studies) because there is a limit of the number of data that can 
be inserted (34). 
 The same exponential group of models can be entered into BMDS and PROAST 
software (Table I). BMDS software provides results for each model entered, 
allowing the user to choose the optimal one, while PROAST automatically 
selects it (34). 
Other differences include the interface of the two software. While BMDS can be 
run immediately and supported by Windows only, PROAST requires the installation and 
prior familiarization with R software. In addition to Windows, it is also supported by 
Linux and Mac operating systems (33, 34). Other significant differences between these 
two software packages can be found in references 33 and 34.  
 In PROAST software, the selection of the optimal model within the exponential 
and/or Hill family of models is made by applying Akaike information criteria (AIC) 
(12,33,37). According to these criteria, the model with the smallest AIC fits data the best. 
Thus, the use of the smallest AIC is recommended even when the differences between 
the values are very small (37). Dose dependence is confirmed in the case when AIC value 
of a specific model is lower than the null model AIC value for more than two units 




dose-dependence, that implies that the dose-effect curve represents the horizontal line (y 
= a). Furthermore, the lowest AIC model value must not surpass the AIC value of the 
specific full model by more than two units (AICmin < AICfull + 2) (29,35). In the 
mathematical equations of the model, y represents the intensity of the effect, x represents 
the dose, while the constants var, a, b, c, and d are the parameters of the curve obtained 
by fitting the model with dose-effect data. Parameter var represents the variance within 
the group. Parameter a represents the effect at zero dose of the so-called background effect 
(vertical curve position parameter), while parameter b represents chemical potency 
(horizontal curve position parameter). Parameter c represents maximum effect intensity 
(M = c for ascending curves, M = 1/c for descending curves) in relation to the background 
effect level (curve shape parameter), while d represents the slope of the curve (curve 
shape parameter) (12,29,33,37). 
 
Table I  Recommended models in the BMD approach  





Full model (i) 




3-parameter model (iii) 
4-parameter model (iv) 
Hill family 
3-parameter model (iii) 









LMS (two-stage) model 
Latent variable models 
(LVMs) based on the 
continuous models 
above (v) 
 (i):  The full model will result in the maximum possible value of the log-likelihood (given the statistical assumptions) for the data 
        set considered. 
(ii):  The null model can be regarded as a model that is nested within any dose–response model: it reflects the situation of no 
        dose response (= horizontal line). 
(iii): Called model 3 in PROAST, and similarly (for the exponential model) in BMDS. 
(iv): Called model 3 in PROAST, and similarly (for the exponential model) in BMDS. 





The BMD approach can be considered a methodically more forward-thinking 
technique in comparison with NOAEL approach. It has statistical power, provides a wide 
range of dose-response data, and allows calculation of their uncertainty and variability. It 
also provides the ability to process old datasets, contributing to the reduction of 
experimental animals. Due to its advantages over the NOAEL approach, the application 
of the BMD approach is recommended in the assessment of genotoxic and carcinogenic 
substances, but also generally in toxicity assessment. It can be used for threshold, but also 
non-threshold effects of a vast number of substances that could threaten not only human 
health but also the environment. In that case, the NOAEL approach would only be used 
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Cilj ovog rada je da predstavi značaj granične benchmark doze (engl. benchmark dose, 
BMD) kao polaznog doznog nivoa (najniže doze ili koncentracije u eksperimentu koja odstupa 
od normalnog odgovora) u toksikološkoj proceni rizika, kao i da prikaže najčešće korišćene 
softvere za njeno izračunavanje (BMDS i PROAST). Benchmark doza predstavlja statističku 
donju granicu pouzdanosti doze koja dovodi do malog povećanja efekta (5-10%) u odnosu na 
kontrolnu vrednost. Benchmark pristup predstavlja alternativu NOAEL (engl. no observed 
adverse effects level, NOAEL) pristupu, u kome se u svrhu dobijanja referentnih vrednosti koristi 
najviša doza koja ne izaziva štetan efekat. Benchmark pristup naučno je napredniji metod od 
tradicionalnog NOAEL pristupa, jer je statistički utemeljen, daje širok opseg podataka o odnosu 
doza-odgovor i omogućava kvantifikaciju njihove nesigurnosti i varijabilnosti. Takođe, BMD 
pristup doprinosi smanjenju broja eksperimentalnih životinja u toksikološkim studijama. Samim 
tim, Evropska agencija za bezbednost hrane (EFSA) preporučuje primenu doza BMDL10 za 
kvantalne i BMDL05 za kontinuirane podatke.  
 
Ključne reči: toksikologija, procena rizika, benchmark doza, PROAST, BMDS 
 
 
